Mutation analysis of PTPN11 in Noonan syndrome by WAVE.
The chapter details the methodology for polymerase chain reaction amplification and WAVE denaturing high-performance liquid chromatography (DHPLC) analysis for all coding exons for the gene PTPNI1, which is mutated in approx 50% of cases of Noonan Syndrome. Although DNA sequencing is initially required to determine the mutation(s) detected by WAVE (sequencing methods are not described in this chapter), each mutation has its own DHPLC signature, and experienced operatives can determine known mutations on this basis. The new Navigator software has made this process more reliable.
Elanko
Navaratnam
N
Genetics Unit, St. George's Hospital, London, United Kingdom.
Jeffery
Steve
S
D002851:Chromatography, High Pressure Liquid; D004247:DNA / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods*; D005091:Exons / Q000235:genetics; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D009634:Noonan Syndrome / Q000235:genetics*; D009691:Nucleic Acid Denaturation; D016133:Polymerase Chain Reaction; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D017027:Protein Tyrosine Phosphatases / Q000235:genetics*; D012984:Software; D013696:Temperature
D047908:Intracellular Signaling Peptides and Proteins; D004247:DNA; C516724:PTPN11 protein, human; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D017027:Protein Tyrosine Phosphatases